Yafei Wang M.D.
Vice Director

Dr.Wang’s clinical interests focus on diagnosis and management of multiple myeloma, leukimia and lymphoma. Hematopoietic Stem Cell Transplantation is also his specialty. He has authored or co-authored more than thirty articles related to these fields. Now He is a member of the blood committee of  China Anti-cancer Association, standing committee of the lymphoma professional committee of Tianjin anti-cancer association. He had a shorted-term advanced training on clinical trails, diagnosis and treatment of blood diseases in Moffitt Cancer Center during 2013.


MAJOR RESEARCH INTERESTS
Diagnosis and management of Multiple Myeloma, leukemia and Lymphoma, Hematopoietic Stem Cell Transplantation

EDUCATION EXPERIENCE

08/2000-07/2005

M.D.in Hematology

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC)


07/1991-07/1996

Bachelor of Medicine

Shandong Medical University

Jinan, P.R. China


 

WORK EXPERIENCE

11/2009-Present

Associate chief physician, Vice director, Executive vice director Hematology department

Tianjin Medical University Cancer Institute and Hospital

Tianjin, P.R. China

07/1996-11/2009

Resident Physician, Attending Physician, Associate chief physician

Chinese Academy of Medical Sciences & Institute of Hematology and Blood Diseases Hospital,

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC)

Tianjin, P.R. China

 
RESEARCH GRANDS
03/2015-03/2018
Science and technology development fund project of universities in Tianjin
Research Program: The mechanisms of 5-ATAN reversing drug-resistance of multiple myeloma through microRNA-21
 
04/2008-04/2011
Tianjin natural science foundation
Research Program: The role of bone remodeling in G-CSF induced mobilization of hematopoietic stem cells.
 
01/2008-01/2011
Fund of Ministry of Education
Research Program: The mechanism of T cell apoptosis induced by CD274.
 
 
PUBLICATIONS
1) Ma Jing#, Tian Chen, Wang Yafei*. Acetabular myeloid sarcoma as an extramedullary presentation of chronic myeloid leukaemia blast crisis. Br J Haematol.2019 Jun 6.
2) Liu S#, Li X, Li Y, Li D, Wang Y*, Tian C*. Multiple myeloma with dural mater involvement. OncoTargets and Therapy. 2019; 12: 3373-3375.
3) Qian Li#, Yuanfang Yue#, Lin Chen , Chang Xu , Yan Wang , Liqing Du, Xiaolei Xue , Qiang Liu*, Yafei Wang* and Feiyue Fan*.Resveratrol Sensitizes Carfilzomib-induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells. Front Pharmacol. 2018;149:334-45.
4) Qian Li#, Shuang Gao#, Jing Ma, Su Liu, Yuanfang Yue, Lin Chen, Han Li, Xue Wang, Dongying Li, Zeng Cao, Zhigang Zhao, Xiaofang Wang, Yong Yu, Yizhuo Zhang, Yafei Wang*, A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified, Leukemia Research, 2018, 73: 5-11
5) Jing Ma#, Wei Gong#, Su Liu, Qian Li, Mengzheng Guo, Jinhan Wang, Suying Wang, Naiyao Chen, Yafei Wang*, Qiang Liu, Hui Zhao*, Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3, Tumor Biology, 2018, 40 (1): 1-10
6) Jing Ma #, Qian Li#, Zhen Yu, Zeng Cao, Su Liu,Lin Chen, Han Li, Shuang Gao, Tinghui Yan, Yafei Wang*,Qiang Liu*, Immunotherapy Strategies Against Multiple Myeloma, Technology in Cancer Research and Treatment, 2017, 12, 16(6): 717-726
7) Yuanfang Yue#, Jing Ma#, Qian Li, Tiantian She, Han Li, Su Liu, Lin Chen, Tinghui Yan, Shuang Gao,Zeng Cao, Yong Yu, Xiaofang Wang, Hongliang Yang, Haifeng Zhao, Yizhuo Zhang, Yafei Wang*, Hashimoto's thyroiditis or/and thyroid cancer in patients with diffuse large B-cell lymphoma, International Journal of Clinical and Experimental Pathology, 2016,9(9): 9547-9554
8) Jianguo Li#, Li Lin#, Liqing Du, Chang Xu, Yan Wang, Jia Cao, Qin Wang, Feiyue Fan, Xiaoping Wang, Yafei Wang*, Qiang Liu*, Radioprotective effect of a pancaspase inhibitor in a novel model of radiation injury to the nucleus of the abducens nerve. Mol Med Rep.2014 Sep;10(3):1433-7
9) Ma J, Wang Y*, Zhao H, Liu S, Li Q, Lin L, Yue Y, Wang X, Zhao Z, Yu Y,ZhangY.Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma.Int J Clin Exp Pathol. 2014 Jul 15;7(8):5045-50


10) Ma J, Liu S, Wang Y*,MicroRNA-21 and multiple myeloma: small molecule and big functionMed Oncol. 2014